P5‐23: Neurological complications of patients with COVID‐19

plex (MAC) was most frequently isolated (86%). Of the patients with MAC, 51% received treatment. The most frequent initial regimen was rifampicin-ethambutolclarithromycin-amikacin (59%). Most (81%) commenced treatment in hospital; the median length of stay was seven days. The median duration of treatment was 18 months. 13 patients (35%) had early cessation of therapy; six stopped treatment within six months. The most common reason was medication intolerance (9/13). Culture conversion was achieved in 62% of patients after a median duration of 6 months. Four patients had refractory disease and four developed recurrent disease. At the end of follow-up, 13/37 and 9/36 of patients had died in the treatment and nontreatment groups, respectively. Conclusions: MAC was the predominant cause of NTMPD. Despite the known high incidence of bronchiectasis in Maori and Pacific Islanders, they were under-represented in this cohort. Treatment complications and early cessation were not infrequent. Mortality was significant irrespective of the treatment decision.